Background {#Sec1}
==========

The discussion of challenges in medical care for elderly patients (65 years and older) is focused on multimorbidity and polypharmacy. Regarding age-related changes in pharmacokinetics and -dynamics, the elderly patients' renal metabolism and clearance as well as first-pass effect in the liver are delayed in time. This causes different actions of drug in geriatric vs. younger patients because the pharmaceutical drugs remain longer in the metabolic system of the elderly \[[@CR1]\].

Prescription of medical drugs in geriatric patients has to consider these effects. But mostly there is no evidence regarding effect of drugs in the elderly. Clinical trials for testing efficacy of drugs often exclude older patients based on an upper-age limit, comorbid disease, reduced life expectancy, physical or mental impairments or use of drugs aiming to minimize biases on outcomes of the study. But the results of efficacy studies that exclude older patients do rarely fit patients in daily medical practice \[[@CR2], [@CR3]\].

Common empirical data show higher hospital admission rates in elderly patients because of adverse drug reactions or drug-drug reactions \[[@CR4]--[@CR6]\]. Regarding this and the complexity of problems with medication for the elderly, expert groups in several countries have developed so called black lists of drugs for elderly patients, describing potentially inappropriate medication (PIM).

Due to different formalities and drug markets, country specific PIM lists are necessary \[[@CR7]\]. These country-specific lists include drugs that are associated with higher risks of intolerance, adverse drug reaction/events or drug-disease interactions in elderly patients \[[@CR8]--[@CR14]\].

In Germany the first black list 'PRISCUS' (PRerequISites for a new health Care model for elderly people with mUltiple morbiditieS) was consensually developed in 2010 by an expert group of geriatrics, pharmacologists and family practitioners. PRISCUS currently includes 83 drugs that should be avoided or prescribed at a lower dose in elderly patients. These recommendations are listed with expert statements offering alternatives. In case of unavoidability of PIM prescriptions, recommendations for drug monitoring are given \[[@CR15]\].

Rates of PIM prescriptions range worldwide between 12 and 65 % depending on the setting and the used screening tool. A systematic review determined a median PIM prescription rate of 20.5 % (interquartile range 18.1 to 25.6 %) in the primary care setting between 1950 and 2011. The review included 19 studies of 11 different countries that examined PIM almost by Beers criteria \[[@CR16]\]. Current studies examining older patient samples (mean age \> 80 years) showed prescription rates between 22.5 and 28.4 % in the primary care setting \[[@CR17], [@CR18]\].

Since these rates seem to be high, it would be useful to understand the prescribing of PIM by family practitioners (FP) to generate feasible and need-oriented solutions for improvement of medical care in the elderly. In this context, more evidence is needed regarding FPs' knowledge of PIM as well as associated recommendations and their acceptance and implementation in daily practice.

There is evidence that polypharmacy increases the risk of PIM in elderly patients \[[@CR6], [@CR18], [@CR19]\]. Furthermore, there are indications that FPs' knowledge of prescribing for the elderly is partly insufficient (more frequently in older FPs) whereas they report a high self-rated confidence in prescribing \[[@CR20]\]. Reported main barriers for appropriate prescribing seem to be related to FPs' lack of education regarding PIM, to organizational characteristics (i.e. lack of time, limited answer options on insurance formularies, communication difficulties with other doctors) and to patients (large number of medications, unknown medications, costs). These findings are based on two smaller studies using a validated survey instrument to examine FPs' knowledge of prescribing for the elderly. Appropriateness was assessed by standardized case vignettes \[[@CR20], [@CR21]\].

Based on the limited knowledge concerning reasons for PIM prescription by FPs we examined reasons for PIM prescription a) in general and b) using real individual case vignettes of FPs that were detected beforehand through record analysis. Aims of this analysis wereto give an overview of rates of PIM prescription in our study sample of elderly multimorbid patients with polymedication in the outpatient primary care setting,to explain influencing factors on prescription of PIM,to examine knowledge and application of PRISCUS andto understand FPs' reasons for prescription of PIM.

Methods {#Sec2}
=======

Our study was coordinated at the Department of General Practice of the Technische Universität (TU) Dresden and took place from March 2013 to June 2014. The study was conducted in cooperation with the Department of Health Care Management and Public Health/Schumpeter School of Business and Economics at the University of Wuppertal.

Study design {#Sec3}
------------

The study was designed as a mixed methods study consisting of three research parts:semi-standardized content analysis of patients' records regarding morbidity, drug prescriptions, admissions/referrals to specialist,qualitative interviews with FPs that focused on challenges and barriers in daily medical care of patients with multimorbidity and polypharmacy using a) open questions to explore these issues in general and b) selected patient-specific case vignettes for each FP based on results of \[[@CR1]\] regarding comparable topics (PIM: prescription of hypnotics; medication change; intersectoral cooperation with in- and out-patient specialists), andqualitative interviews with their medical assistants to explore their point of view regarding organization-related barriers, challenges and room for improvement for medical care of patients with multimorbidity and polypharmacy \[[@CR22]\].

Results of qualitative interviews with FP and their medical assistants were used to help explain the quantitative results (triangulation design \[[@CR23]\]). More detailed information on our study design, setting and research instruments are already published elsewhere \[[@CR24]\].

This publication focuses on results of subanalysis of research parts (1) and (2) regarding the prescription of PIM by FPs.

Inclusion of study participants {#Sec4}
-------------------------------

All 33 FPs from academic teaching practices of the Department of General Practice of TU Dresden situated in Dresden were invited for participation in the study. After confirmation of participation by the FPs, all chronic patients of each participating practice were invited for participation if they met following inclusion criteria: a) at least two parallel chronic diseases and b) two prescribed long-term medications at least 6 months before 2012. Furthermore, all medical assistants of the participating FPs were asked to participate in qualitative interviews.

Data collection {#Sec5}
---------------

Patients' records \[[@CR1]\] were analyzed from March 2013 to May 2014 by our project assistants at FPs' practices using a semi-standardized entry mask in SPSS 22.0. Patient records of a randomized quarter of the year 2012 were retrospectively analyzed per patient, and information regarding morbidity, admissions/referrals to specialists and non-drug and drug prescriptions (including documented adverse events) were documented. Prescriptions by specialists were only included if FPs had documented them in the patient records based on the findings reports sent by the specialists or direct information by the patients.

The quarters were assigned randomly to each patient. Qualitative face-to-face interviews \[[@CR2]\] were conducted by 2 experienced interviewers (scientific project staff) with 7 FPs around 2--3 weeks after finishing record analysis. Interviews took place in FPs' practices and each interview lasted between 40 and 60 min. Confronting FPs with their real-life decisions in individual case vignettes that were chosen from analyzed patients' records (see Table [1](#Tab1){ref-type="table"}) we asked themTable 1Description of case vignettes regarding documented prescription of PIMFPDocumented chronic conditions of the case (ICD-10)Documented acutediagnosis of the case (ICD-10)Prescription of PIM per quarter: agents/amount (prescribed daily dosage)Further agents for long-term treatment/same quarterFP1D25: Leiomyoma of uterusF43: Reaction to severe stress, and adjustment disordersZolpidem/80 pellets (missing)Candesartan, Carbamazepine, Doxepin, Gabapentin, Metoprolol, Metformin, PravastatinE22: Hyperfunction of pituitary glandE78: Disorders of lipoprotein metabolismG25: Other extrapyramidal and movement disordersG47: Sleep disordersG56: Mononeuropathies of upper limbG58: Other mononeuropathiesI10: Essential (primary) hypertensionI65: Occlusion and stenosis of precerebral arteriesR55: Syncope and collapseFP2F13: Mental and behavioral disorders due to use of sedatives or hypnoticsM54: DorsalgiaZopiclone/60 pellets (7.5 mg/day), Lorazepam/missing (2.5 mg/day)Acetylsalicylic acid, Amlodipine, Calcitrol, Carvedilol, Cholecalciferol, Minoxidil, Mirtazapine, Pantoprazole, Torasemide, ValsartanF34: Persistent mood \[affective\] disordersF40: Phobic anxiety disorders G47: Sleep disordersI10: Essential (primary) hypertensionN18: Chronic kidney diseaseT88: Other complications of surgical and medical care, not elsewhere classifiedFP3E03: HypothyroidismJ06: Acute upper respiratory infections of multiple and unspecified sitesZolpidem/80 pellets (10 mg/day)Beclomethasone, Bisoprolol, Cobalamin, Duloxetine, Hydrochlorothiazide, Lactulose, Levothyroxine, Metoclopramide, Omeprazole, Salbutamol, Tramadol,E53: Deficiency of other B group vitaminsI35: Nonrheumatic aortic valve disorders I50: Heart failureK29: Gastritis and duodenitisM48: Other spondylopathiesQ61: Cystic kidney diseaseR15: Faecal incontinenceR52: Pain, not elsewhere classifiedFP4D86: SarcoidosisnoneZolpidem/100 pellets (10 mg/day)Hydrochlorothiazide, Naloxone, Nitrendipine, Pregabalin, Tilidine, ValsartanE78: Disorders of lipoprotein metabolism and other lipidaemiasG47: Sleep disordersH53: Visual disturbancesI10: Essential (primary) hypertensionI83: Varicose veins of lower extremitiesM25: Other joint disorders, not elsewhere classifiedM81: Osteoporosis without pathological fractureN17: Acute renal failureR26: Abnormalities of gait and mobilityZ93: Artificial opening statusFP5C80: Malignant neoplasm, without specification of siteR07: Pain in throat and chestZopiclone/missing (7.5 mg/day)Bisoprolol, Hydrochlorothiazide, Ramipril, Trimipramine, Pantoprazole, Acetylsali-cylic acid, IbuprofenH53: Visual disturbancesI10: Essential (primary) hypertensionI27: Other pulmonary heart diseasesI34: Atrial fibrillation and flutterK43: Ventral herniaR26: Abnormalities of gait and mobilityZ93: Artificial opening statusZ96: Presence of other functional implantsFP6E11: Type 2 diabetes mellitusnoneZopiclon/120 pellets (missing)Allopurinol, Amlodipine, Enalapril, MoxonidineI10: Essential (primary) hypertensionI50: Heart failureM10: GoutN08: Glomerular disorders in diseases classified elsewhereN18: Chronic kidney diseaseFP7E78: Disorders of lipoprotein metabolism and other lipidaemiasM54: DorsalgiaZopiclon/180 pellets (7.5 mg/day)Allopurinol, Felodipine, Metoprolol, OlmesartanE79: Disorders of purine and pyrimidine metabolismF51: Nonorganic sleep disorders I10: Essential (primary) hypertensionJ44: Other chronic obstructive pulmonary diseaseto explain their case-related decisions of the prescription of a PIM substance and influencing factors on it for the respective case vignette,to discuss reasons for prescription of PIM in contrast to known recommendations generally andto assess their knowledge, usage and acceptance of recommendations in daily practice (German PRISCUS-list).

We used these real-life case vignettes to get more authentic answers by FPs and as concrete starting points for reflection of the PIM-topic in general. One patient (\>65 years) with the most prescription of benzodiazepine receptor agonists (so called Z-drugs) not corresponding to recommendations of PRISCUS per each FP was selected for the respective case vignette (see Table [1](#Tab1){ref-type="table"}).

Analysis {#Sec6}
--------

Statistical analysis of data based on record analysis \[[@CR1]\] were done using SPSS 22.0 to describe characteristics of the sample of patients \> 65 years and especially of the subsample affected by PIM prescription. Screening all documented prescribed drugs, PIM were identified according to the German PRISCUS list. Differences in distributions were examined using chi^2^-test. *T*-test for unpaired samples was conducted to examine differences of means between different groups. A logistic regression was conducted to identify predictors for PIM-prescription.

The procedure of qualitative content analysis of interviews with FPs \[[@CR2]\] is based on Mayring \[[@CR25]\]. Two researchers analyzed the interview manuscripts by using MAXQDA® software to categorize contextual factors and individual reasons for PIM prescription from FPs' point of view. The contents of the interviews were classified inductively to indicate pertinent categories. The derived categories were discussed and consented in the research team.

All data were pseudonymously recorded and analyzed. For integrating results, interview data (e.g. reported motives of prescription) were triangulated with data based on patient records' analysis (e.g. relative frequencies of PIM prescription).

Results {#Sec7}
=======

Description of participating family physicians {#Sec8}
----------------------------------------------

Out of 33 academic teaching physicians of the Department of General Practice of TU Dresden, working in Dresden, 7 (of which 5 were female) participated in this study. The age of the participants was distributed between 43 and 61 years, and professional experiences were reported between 7 and 22 years. Out of 7 FPs, 3 worked at group practices and 4 at single practices, At the FPs' practices, between 2 and 6 medical assistants were employed.

Of all the 7 FPs' patients a number of 2826 met the inclusion criteria (≥2 chronic conditions and ≥ 2 related long-term medication), and 1846 patients (65.3 %) gave their consent for participation in the study. The number of participating patients per FP varied between a minimum of 120 and a maximum of 455. 55 % were females, and the age distribution was between 23 and 100 years with a mean age of 69 (±11 SD) years. 69.4 % of the patients were \> 65 years old who will be in focus of following analysis.

Based on the small sample of participating FPs, the results of the study are limited regarding representativeness of FPs and patients. To check for potential biases we compared our data with results of comparable studies (external validation, see below).

Description of the sample: elderly patients {#Sec9}
-------------------------------------------

Elderly patients \[*n* = 1241, mean age: 76 (±6 SD), females: 56.6 %\] were characterized in average by 8.3 \[(±3.7 SD\] documented chronic diagnosis (ICD 10) that include a total of 543 different ICD-Codes (shortened to first figure).

Most prevalent diagnosis described typical medical conditions of the metabolic syndrome: for 84.0 % of patients \> 65 years essential hypertension (I10), for 49.3 % lipometabolic disorders (E78) and for 39.3 % diabetes mellitus 2 (E11) was documented (see Table [2](#Tab2){ref-type="table"}). In 16.1 % of cases there was a co-occurrence of these three diagnoses as a hint for prevalence of a metabolic syndrome.Table 2Top Ten of documented chronic and acute diagnosis in patients \> 65 years (*n* = 1241)Chronic diagnosisAbsolute frequencyRelative frequencyAcute diagnosisAbsolute frequencyRelative frequencyI10Essential hypertension107684.0M54Dorsalgia385.4E78Dyslipidemia63249.3J06Acute upper respiratory infections355.0E11Diabetes mellitus type 250339.3N39Other disorders of urinary system233.3I25Chronic ischaemic heart disease42232.9R10Abdominal and pelvic pain223.1M81Osteoporosis20916.3R21Rash and other nonspecific skin eruption223.1I83Varicosis of lower extremities19315.1M53Other dorsopathies, not elsewhere classified213.0I48Atrial flutter/fibrillation19315.1F43Reaction to severe stress213.0Z92long-term (current) use of anticoagulants18314.3M25Other joint disorders, not elsewhere classified192.7M17Gonarthrosis18214.2G47Sleep disorders152.1E79Disorders of purine and pyrimidine metabolism16312.7F32Depressive episode142.0

65.5 % of the elderly patients were given 4 and more drugs in long term medications (M: 6.3 ± 3.3 SD). The number of prescribed drugs correlated not very strongly with the number of chronic diagnosis (*r* = 0.34/*p* ≤ 0.001).

Regarding the interpretation of documented chronic diagnoses the limitation of validity based on missing or unspecific diagnoses needs to be considered. Patients' records consist on information about chronic diagnoses documented primary for billing purposes. Although billed drugs and medical services need to be confirmed by documenting associated diagnoses, mismatches were found in our data. An exemplary analysis regarding congruence of prescriptions of thyroid medications and associated thyroid diagnosis showed insufficiently documented thyroid diagnosis in 26.8 % of patients with diagnosed or treated thyroid diseases \[[@CR26]\].

Prescription of potentially inappropriate medication {#Sec10}
----------------------------------------------------

Out of the 83 PIM in the German PRISCUS list (including inappropriate drugs and in some cases inadequately dosed drugs), 41 PIM were prescribed in our sample. Using the method of record analysis, our data include all of FPs' documented drug prescriptions, incl. private prescriptions that are not covered by the statutory health insurance respectively over the counter medication. Prescriptions by specialists were only included if FP had been informed and documented it. Since our data are related to FP prescription, the real PIM-prescription in general will be underestimated.

To summarize, 23.9 % of elderly patients received at least one PIM prescription, which is comparable to other studies reporting PIM prescription rates between 22.5 and 28.4 % of elderly patients in the primary care setting \[[@CR17], [@CR18]\]. 21.5 % of patients in our study got at least one PIM as medication for chronic conditions and 3.1 % to care for acute symptoms. Sedatives and hypnotics were the most frequent (13.7 %) prescribed PIM-drugs in patients \> 65 years (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Frequencies of prescribed PIMs summarized in agents groups in elderly patients (*n* = 1241)

Zopiclon (4.3 %), Zolpidem (2.3 %), Diazepam and Doxacosin (each 1.9 %) were the top-3-PIM in our sample (see Table [3](#Tab3){ref-type="table"}). This is different to results of Zimmermann et al. (2013) who showed highest rate of PIM prescription in the agent group of antidepressants \[[@CR18]\]. Since antidepressants and sedatives/hypnotics as most described PIM are commonly given for mental disorders, we examined the proportion of patients with one (or more) related diagnose(s) in our sample. 20.5 % of all patients \> 65 years suffered from at least one documented mental disorder (ICD-10, chapter F). Based on this, the differences between our and Zimmermann's data, concerning the highest rate of PIM prescriptions (as described above), could be explained by the difference in prevalence of depression: whereas 9.4 % of all patients in our sample suffered a documented form of depression, in Zimmermann's sample there were 12.2 % cases of depression at base line, age-related increasing to \> 20 % in the follow-ups \[[@CR18]\].Table 3Top Ten of the prescribed PIM in elderly patients \> 65 years (*n* = 1241)RangeAgentTotal frequencyTotal frequency (%)1Zopiclone (\>3.75 mg/d)534.32Zolpidem (\>5 mg/d)292.33Diazepam241.9Doxazosin241.94Nifedipine231.95Etoricoxib181.56Medazepam171.47Lorazepam (\>2 mg/d)161.38Brotizolam (\>0.125 mg/d)151.29Amitryptiline131.1Nitrazepam131.110Indomethacin101.0

A significantly higher number of female (F: 27.6 % vs. M: 19.1 %, *χ*^2^ = 12.0/*p* ≤ 0.001) and very old patients (≥80 years: 31.3 % vs. \< 80 years: 21.6 %, *χ*^2^ = 11.7/*p* ≤ 0.001) received a PIM prescription. Patients with at least one PIM prescription were characterized by a significantly higher number of chronic diagnoses (M 9.3 ± 3.9 SD) and long-term medication (7.5 ± 3.7 SD) compared to patients without a PIM prescription (8.0 ± 3.6 SD/*t*-test: *p* ≤ 0.001 respectively 5.4 ± 3.0 SD, *t*-test: *p* ≤ 0.001).

Influencing factors on prescription of PIM {#Sec11}
------------------------------------------

Conducting a logistic regression, we examined the influence of binary associated factors on prescription of PIM in a multivariate model. Including gender, age, documented diagnose of a mental disorder (ICD-10: F), number of diagnoses and number of long-term medication in the regression model, the strongest effect was detected for documented mental disorders (Exp(B) = 2.0/*p* ≤ 0.001), followed by female gender (Exp(B) = 1.6/*p* ≤ 0.01) and number of long-term medication (Exp(B) = 1.2/*p* ≤ 0.001) as predictors for the probability of a PIM prescription. Age and number of diagnoses were not predictive for PIM prescription. The three mentioned predictors explained just 14.9 % of the variance (Nagelkerkes R^2^ = 0.149) of the dependent variable. However, there will be other influencing variables we did not include in the model. Our findings are comparable to other studies that found depression as one of the common mental disorders in elderly patients as main predictor (OR = 2.42) for PIM prescription, followed by the number of prescribed drugs (OR = 1.99) \[[@CR18]\]. A positive correlation between the number of prescribed drugs and the risk of PIM in the elderly was also shown in the study of Schubert \[[@CR19]\].

Knowledge and application of PRISCUS-list {#Sec12}
-----------------------------------------

PRISCUS was generally known by 5 of 7 interviewed FPs, but the application of the list in daily practice diverged between the interviewees. Several FPs reported its use in daily practice as an instrument for orientation. Others denied or refused to use the list using different arguments pro and contra PRISCUS (see Table [4](#Tab4){ref-type="table"}). Skeptical arguments regarding applicability in daily practice and its benefits for individual patients within the complex context of multimorbidity were reported commonly:Table 4Pros and Cons of the PRISCUS-list from FPs' point of viewFPs' arguments pro PRISCUSFPs' arguments contra PRISCUS•Includes no-go-medication you have to remember every timeNot practicable in FPs' daily practice since•Good for orientation•does often not fit individual patients' needs•Possible argument if FP wants to refuse a medication•within its complex context of multimorbidity•does not recommend practicable and pharmacologically based alternatives•does not fit experience-based practice•does not fit patient demands for a certain PIM based on individual positive experiences•limited time in consultations a) to check additional recommendation lists and b) to convince patients for new medication•chronological age does not match biological age: lot of patients \> 65 years have a younger biological age•mistrust in PRISCUS based on missing evidence for medication of multimorbid elderly patients"*Yes, both me and my colleagues have a short version pinned up at our desks. But if you look at the list you get lost even before the consultation with the patient starts. It is not useful at all, unless you want to refuse a prescription of a medication, of course. \[FP6\]*"

The inherent problem of lack of time (the average duration of consultation at FPs' practices is ca. 8 min per patient in Germany \[[@CR27]\]) was mentioned by most of the FPs. This finding is comparable to other studies that also pointed out lack of time as a main barrier for appropriate prescribing \[[@CR20], [@CR21]\] or for implementing recommendations of guidelines in daily practice \[[@CR28]\].

Several FPs were doubtful regarding the evidence of PRISCUS list since most of pharmacological studies exclude elderly patients, and therefore related evidence is missing. Other studies also showed partly existing skeptical attitudes of physicians regarding cited evidence in guidelines \[[@CR29]\]. Two FPs criticized that the PRISCUS list does not recommend *"practicable and pharmacologically based alternatives" \[FP6\]*. For instance, regarding the prescription of sedatives/hypnotics, FPs reported great uncertainty (see below).

One FP argued that primary care physicians mostly act intuition- and experience-based. From his point of view, evidence-based practice that includes implementation of guidelines in daily practice would not be typical for FPs' practice. Triangulating these interview data with related data of patient records' analysis, we detected that this intuition- and experience-oriented FP had a visibly lower prescription rate of PIM while reporting the highest proportion of patients \> 65 years. Nevertheless, this single example might not be representative for all FPs. However, intuition-based and evidence-based acting do not exclude each other in the dichotomous way of a "zero-sum relationship" \[[@CR30]\].

Social desirability was assumed in some FPs who reported knowing PRISCUS. Asked for their concrete criticisms they first reported weakness of PRISCUS list in general, and, after repeating the question, they apologized for not remembering since they do not use the list. There were two FPs knowing nothing of PRISCUS and PIM at all. This is similar to results of other studies describing educational lacks in primary care as well as hospital physicians, regarding appropriate prescribing in elderly patients \[[@CR20], [@CR21]\].

Reported causes for prescription of potentially inappropriate medication {#Sec13}
------------------------------------------------------------------------

Most reported cause for PIM prescription was the statement of unavoidability of PIM because having no alternatives in medication, especially in multimorbid patients. FPs prescribing PIM appreciated the related higher risk for unexpected medication-related events and reported to re-consult these patients in shorter periods."*Regarding polypharmacy, there are no convincing recommendations as to what to prescribe as an alternative. Full stop. That is why I consult these patients (note: with PIM) closely. I will see them several times in the quarter at my practice to keep a close eye on them. \[FP2\]*""*(Note: As with PIM) you have similar issues with these huge amounts of pain pellets or patients receiving Falithrom (note: Phenprocoumon). Every time something can happen. But this is unavoidable, isn't it? \[FP5\]*"

Further arguments are related to FPs' prioritization regarding therapeutic objectives. There are stronger patient-related factors than age that influence their decision of a certain medication. Based on this, the PIM-topic could become less important:"*If you keep the wellbeing of the patient as the primary goal in mind, then a lot will be sorted based on this prioritization. Age seems to be a difficult criterion in general, so patients' health status and perspectives should be more important. \[FP2\]*""*Regarding sedatives, benzodiazepine vs. z-drugs it is like being caught between a rock and a hard place. I am certain that it (note: PIM) is not recommended by PRISCUS but there are no alternatives. And the patient needs to get sleep and be pain-free from time to time. So we talk to the patient about the medication, how to limit it time-wise and how to monitor it closely. \[FP1\]*"

Own bad experiences regarding a) change of medication to avoid PIM and b) refusal of following prescription of sedatives/hypnotics (that also belong to PIM if certain dosage is reached) to addicted patients resulted in a kind of resignation."*You can start making changes in medication, yes, but most of them are not successful. \[FP1\]*"

In context of FPs' care for patients who are addicted to hypnotics, PIM-topic seemed to become subordinated whereas treatment of addiction got into the main focus:"*Well, you can speak like a priest in the church: if patients have a certain level of addiction it is really difficult. I could refuse them the medication, but then they will go to a different \[physician\], so this doesn't make any sense. \[FP7\]*"

This finding is convenient to our previous result of the logistic regression (see above), showing that a documented mental disorder was the strongest predictor for prescription of PIM.

Most of the interviewed FPs described the advantages of caring primarily for patients addicted to hypnotics because getting them under control in "one hand". But finally they seem to be still perplexed:"*I had special cases of patients, when I said, okay, let's keep them in "one hand" and see if we can somehow take responsibility for it. Yes, we try to care for them individually. Last time I had a patient, she picked up sleeping pills from her neurologist, from me and from another GP. And then at night she had a bad fall because she was just completely in the swash. Finally she was hospitalized, but how to manage her? I have no magic remedy for this problem. \[FP4\]*"

Most of the FPs described the importance of close cooperation with neurologists/psychiatrists regarding care for patients addicted to hypnotics, but several problems were pointed out. First, they reported patients' difficulties to get access to a psychiatrist for "just" sleeping disorders and second, they reported communication lacks regarding prescriptions of medications and lacks in referral of clinical information. And third, some of the FPs pointed out an uncritical prescribing by psychiatrists without looking at the patient in their entirety including existing multimorbidity. But especially in the case of out-patient detoxification, FPs underlined the necessity of cooperation. To summarize, most of the FPs saw great challenges and chances in a better cooperation with psychiatrists to improve medical care for (elderly) patients addicted to hypnotics.

Conclusion {#Sec14}
==========

This is to our best knowledge the first published study triangulating PIM prescription data based on the analysis of patients' records with qualitative interview data regarding case-related motives of PIM prescription. In summary, prescription of PIM was mainly a topic of chronic disease treatment. We find out that it is essential to see FPs in a complex decision making situation with several influencing factors on their prescribing, including:patient-oriented prioritization reflecting i.e. multimorbidity and related polypharmacy, existing mental disorders, gender, patients' requests \[[@CR29]\] and experiencesFPs' experiences in daily practice \[[@CR29]\] regarding e.g. (inter) actions of drugs \[[@CR31]\], reactions of patients in case of refusal or change of a drugFPs' knowledge regarding e.g. existing evidence/recommendations and their trust in itdependent on quality of cooperation with in- and out-patient specialist; forwarded information regarding clinical indication and prescribed drugsorganizational characteristics, i.e. lack of time in daily practice, follow-up prescriptions of PIM initially prescribed by specialists.

Obviously, there is a problem with the applicability of guidelines and recommendations, rooted in the special characteristics of FPs´ work: the individual consideration of decisions against the background of the knowledge of the patient's medical history, patient´s characteristics and suspected adherence.

Partly, FPs reported to be not really convinced of their decisions foreseeing associated higher risks of drug related adverse events. Assuming that they will not find medication alternatives for individual multimorbid patients, frequently re-consultations and laboratory tests were seen as methods to detect drug related problems as soon as possible.

The partly detected education lack regarding PIM and PRISCUS shows challenges for further educational tasks that should take the partly missing trust in recommendation and PRISCUS into account even though influence of new guidelines and their recommendations on physicians' daily practice seems to be limited \[[@CR29]\].
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